Page 110 - Programme book for The International Liver Congress 2015, EASL ILC 2015
P. 110
Late Breakers (Cont.) Hall D
ABSTRACT A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED
LO4 STUDY (IMAGO) OF LUM001, A NOVEL INHIBITOR
16:45-17:00 OF THE APICAL SODIUM-DEPENDENT BILE ACID
TRANSPORTER, (ASBT) IN PAEDIATRIC PATIENTS WITH
ALAGILLE SYNDROME (ALGS)
Alastair Baker, The United Kingdom
ABSTRACT SOFOSBUVIR + PEGINTERFERON/RIBAVIRIN FOR 12
LO5 WEEKS VS SOFOSBUVIR + RIBAVIRIN FOR 16 OR 24
17:00-17:15 WEEKS IN GENOTYPE 3 HCV INFECTED PATIENTS AND
TREATMENT-EXPERIENCED CIRRHOTIC PATIENTS
WITH GENOTYPE 2 HCV: THE BOSON STUDY
Graham Foster, The United States
ABSTRACT A TWO-STAGE GENOME-WIDE ASSOCIATION STUDY
LO6 IDENTIFIES TM6SF2 AND MBOAT7 AS RISK LOCI FOR
17:15-17:30 ALCOHOL–RELATED CIRRHOSIS
Felix Stickel, Switzerland
ABSTRACT A SINGLE SUBCUTANEOUS DOSE OF 2 MG/KG
LO7 OR 4 MG/KG OF RG-101, A GALNAC-CONJUGATED
17:30-17:45 OLIGONUCLEOTIDE WITH ANTAGONIST ACTIVITY
AGAINST MIR-122, RESULTS IN SIGNIFICANT VIRAL
LOAD REDUCTIONS IN CHRONIC HEPATITIS C
PATIENTS
Meike Van Der Ree, The Netherlands
ABSTRACT DACLATASVIR, SOFOSBUVIR, AND RIBAVIRIN
LO8 COMBINATION FOR HCV PATIENTS WITH ADVANCED
17:45-18:00 CIRRHOSIS OR POSTTRANSPLANT RECURRENCE:
PHASE 3 ALLY-1 STUDY
Fred Poordad, The United Kingdom
EASL Business Meeting Stolz 1
18:15 - 19:30 Access restricted to active EASL members
Abdominal Sonography Course - ‘Acute Medicine’ in Hepatology Lehar 3
18:30 - 20:00 Tutors:
Robert de Knegt, The Netherlands
Michael Gebel, Germany
Andrej Potthoff, Germany
Dave Sprengers, The Netherlands
Pavel Taimr, The Netherlands
Christoph Terkamp, Germany
ABSTRACT A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED
LO4 STUDY (IMAGO) OF LUM001, A NOVEL INHIBITOR
16:45-17:00 OF THE APICAL SODIUM-DEPENDENT BILE ACID
TRANSPORTER, (ASBT) IN PAEDIATRIC PATIENTS WITH
ALAGILLE SYNDROME (ALGS)
Alastair Baker, The United Kingdom
ABSTRACT SOFOSBUVIR + PEGINTERFERON/RIBAVIRIN FOR 12
LO5 WEEKS VS SOFOSBUVIR + RIBAVIRIN FOR 16 OR 24
17:00-17:15 WEEKS IN GENOTYPE 3 HCV INFECTED PATIENTS AND
TREATMENT-EXPERIENCED CIRRHOTIC PATIENTS
WITH GENOTYPE 2 HCV: THE BOSON STUDY
Graham Foster, The United States
ABSTRACT A TWO-STAGE GENOME-WIDE ASSOCIATION STUDY
LO6 IDENTIFIES TM6SF2 AND MBOAT7 AS RISK LOCI FOR
17:15-17:30 ALCOHOL–RELATED CIRRHOSIS
Felix Stickel, Switzerland
ABSTRACT A SINGLE SUBCUTANEOUS DOSE OF 2 MG/KG
LO7 OR 4 MG/KG OF RG-101, A GALNAC-CONJUGATED
17:30-17:45 OLIGONUCLEOTIDE WITH ANTAGONIST ACTIVITY
AGAINST MIR-122, RESULTS IN SIGNIFICANT VIRAL
LOAD REDUCTIONS IN CHRONIC HEPATITIS C
PATIENTS
Meike Van Der Ree, The Netherlands
ABSTRACT DACLATASVIR, SOFOSBUVIR, AND RIBAVIRIN
LO8 COMBINATION FOR HCV PATIENTS WITH ADVANCED
17:45-18:00 CIRRHOSIS OR POSTTRANSPLANT RECURRENCE:
PHASE 3 ALLY-1 STUDY
Fred Poordad, The United Kingdom
EASL Business Meeting Stolz 1
18:15 - 19:30 Access restricted to active EASL members
Abdominal Sonography Course - ‘Acute Medicine’ in Hepatology Lehar 3
18:30 - 20:00 Tutors:
Robert de Knegt, The Netherlands
Michael Gebel, Germany
Andrej Potthoff, Germany
Dave Sprengers, The Netherlands
Pavel Taimr, The Netherlands
Christoph Terkamp, Germany
